Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece.

Grivea IN, Sourla A, Ntokou E, Chryssanthopoulou DC, Tsantouli AG, Syrogiannopoulos GA.

BMC Infect Dis. 2012 Oct 11;12:255. doi: 10.1186/1471-2334-12-255.

2.

Methods of detection of circulating melanoma cells: a comparative overview.

Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, Gogas H, Stratigos AJ, Katsambas AD, Koutsilieris M.

Cancer Treat Rev. 2011 Jun;37(4):284-90. doi: 10.1016/j.ctrv.2010.10.002. Epub 2010 Nov 23. Review.

PMID:
21106295
3.

uPA, uPAR and TGFβ₁ expression during early and late post myocardial infarction period in rat myocardium.

Stavropoulou A, Philippou A, Halapas A, Sourla A, Pissimissis N, Koutsilieris M.

In Vivo. 2010 Sep-Oct;24(5):647-52.

PMID:
20952728
4.

Insulinlike growth factor-1Ec (MGF) expression in eutopic and ectopic endometrium: characterization of the MGF E-peptide actions in vitro.

Milingos DS, Philippou A, Armakolas A, Papageorgiou E, Sourla A, Protopapas A, Liapi A, Antsaklis A, Mastrominas M, Koutsilieris M.

Mol Med. 2011 Jan-Feb;17(1-2):21-8. doi: 10.2119/molmed.2010.00043. Epub 2010 Sep 14.

5.

Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells.

Armakolas A, Philippou A, Panteleakou Z, Nezos A, Sourla A, Petraki C, Koutsilieris M.

Prostate. 2010 Aug;70(11):1233-42. doi: 10.1002/pros.21158.

PMID:
20564425
6.

Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro.

Philippou A, Papageorgiou E, Bogdanis G, Halapas A, Sourla A, Maridaki M, Pissimissis N, Koutsilieris M.

In Vivo. 2009 Jul-Aug;23(4):567-75.

7.

Systemic cytokine response following exercise-induced muscle damage in humans.

Philippou A, Bogdanis G, Maridaki M, Halapas A, Sourla A, Koutsilieris M.

Clin Chem Lab Med. 2009;47(6):777-82. doi: 10.1515/CCLM.2009.163.

PMID:
19445648
8.

IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro.

Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A, Koutsilieris M.

Mol Med. 2009 May-Jun;15(5-6):127-35. doi: 10.2119/molmed.2009.00012. Epub 2009 Mar 6.

9.

Detection of circulating tumor cells in bladder cancer patients.

Nezos A, Pissimisis N, Lembessis P, Sourla A, Dimopoulos P, Dimopoulos T, Tzelepis K, Koutsilieris M.

Cancer Treat Rev. 2009 May;35(3):272-9. doi: 10.1016/j.ctrv.2008.11.003. Epub 2008 Dec 21. Review.

PMID:
19103472
10.

Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, Koutsilieris M.

Mol Med. 2009 Mar-Apr;15(3-4):101-14. doi: 10.2119/molmed.2008.00116. Epub 2008 Dec 3. Review.

11.

Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance.

Nezos A, Lembessis P, Sourla A, Pissimissis N, Gogas H, Koutsilieris M.

Clin Chem Lab Med. 2009;47(1):1-11. doi: 10.1515/CCLM.2009.009. Review.

PMID:
19055471
12.

Characterization of a rabbit antihuman mechano growth factor (MGF) polyclonal antibody against the last 24 amino acids of the E domain.

Philippou A, Stavropoulou A, Sourla A, Pissimissis N, Halapas A, Maridaki M, Koutsilieris M.

In Vivo. 2008 Jan-Feb;22(1):27-35.

13.

Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.

Lembessis P, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, Milathianakis C, Bogdanos J, Papaioannou A, Maragoudakis E, Dardoufas C, Dimopoulos T, Koutsilieris M.

Clin Chem Lab Med. 2007;45(11):1488-94.

PMID:
17924845
14.
15.

Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.

Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A.

BJU Int. 2007 Jul;100 Suppl 2:60-2. Review. No abstract available.

16.
17.

Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics.

Mitropapas G, Nezos A, Halapas A, Pissimissis N, Lembessis P, Sourla A, Vassilopoulos P, Koutsilieris M.

Clin Chem Lab Med. 2006;44(12):1403-9.

PMID:
17163814
18.

Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).

Karamanolakis D, Lambou T, Bogdanos J, Milathianakis C, Sourla A, Lembessis P, Halapas A, Pissimissis N, Dessypris N, Petridou ET, Koutsilieris M.

Anticancer Res. 2006 Jul-Aug;26(4B):3159-66.

19.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.

Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.

Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. Review.

PMID:
16787142
20.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk